Oncocyte Corporation's shareholders have approved a proposal for the board of directors to execute a reverse stock split at any specified ratio within a year. On July 24, 2023, the board approved a one-for-twenty reverse stock split to comply with the Nasdaq Stock Market's minimum bid price listing requirement. The reverse stock split will be effective as of 5:00 p.m. Pacific time on July 24, 2023.